PEDIATRICS Vol. 72 No. 4 October 1983, pp. 581-582
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ELLISON, R. C.
Right arrow Articles by NADAS, A. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by ELLISON, R. C.
Right arrow Articles by NADAS, A. S.

The Silent Patent Ductus Arteriosus

R. CURTIS ELLISON MD1, GEORGE J. PECKHAM MD1, PETER LANG MD1, NORMAN S. TALNER MD1, TRUDY S. LERER MS1, LILLIAN LIN MS1, KENNETH J. DOOLEY MD1, and ALEXANDER S. NADAS MD1

1 National Collaborative Study on Patent Ductus Arteriosus in Premature Infants, Coordinating Center: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115

In Reply.—

We appreciate the comments of Kashani, Swensson and Merritt. We are cognizant of the pioneering work done through the years at the University of California at San Diego in relation to the management of respiratory distress syndrome (RDS).

The multicenter trial1 established diagnostic criteria for patent ductus arteriosus (PDA) in 1978. In view of the unknown toxicity of indomethacin at that time, high specificity rather than maximum sensitivity was of prime concern. We wanted to enroll in our trial only those infants in whom the degree of ductal shunting was leading to sufficient cardiopulmonary compromise to cause a threat to the infant and to warrant the use of a potentially toxic drug or surgery.